We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Tumor Regression with New Antibody-Drug Conjugate
Product News

Tumor Regression with New Antibody-Drug Conjugate

Tumor Regression with New Antibody-Drug Conjugate
Product News

Tumor Regression with New Antibody-Drug Conjugate


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Tumor Regression with New Antibody-Drug Conjugate"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Iksuda Therapeutics (Iksuda), a developer of next generation Antibody Drug Conjugates (ADCs), has announced the first data on its lead ADC, IKS01. IKS01, an ADC targeting the folate receptor, has shown significant anti-tumor efficacy in pre-clinical models of ovarian and lung tumors, each of which included a broad range of folate-receptor alpha (FRA) expression. The data was presented at ESMO Congress 2019 in Barcelona, Spain.

ADCs allow for the targeted delivery of a potent cytotoxic payload to tumors, resulting in selective killing with increased efficacy and less off-target toxicity than standard-of-care chemotherapies. Frequent over-expression of FRA in ovarian and non-small-cell lung cancer (accounting for 80% of lung cancer cases) and relative lack of expression in normal tissue, make it an attractive therapeutic target. However, anti-tumor activity is generally limited to patients whose tumors express high levels of FRA.

IKS01 is an ADC comprised of an FRA-targeting antibody conjugated via Iksuda’s PermaLink® technology to Femtogenix’s highly potent FGX2-62 payload. IKS01 is target specific and these new data confirm that it is highly effective in causing tumor regression in FRA-expressing models at doses that are well-tolerated, significantly more active than a benchmark ADC and caused complete regressions in low/moderate FRA-expressing models.

The IKS01 data is a major advancement of Iksuda’s ADC drug pipeline, from which it aims to progress multiple candidates towards first clinical studies in 2020.

Dave Simpson PhD, Chief Executive Officer, Iksuda Therapeutics, said: “Ovarian cancer is one of the most deadly gynaecological cancers and lung cancer remains a leading cause of cancer-related death. The IKS01 data highlight the potential impact of our ADC pipeline by targeting difficult-to-treat tumors and advancing current standard of care.” 

Advertisement